US FDA approves Vanda Pharmaceuticals' motion sickness drug
Dec 30 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' VNDA.O drug for the prevention of vomiting induced by motion, the company said on Tuesday. (Reporting by Siddhi Mahatole and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar) ((siddhi.mahatole@thomsonreuters.com;))
Recent news on Prestige Consumer Healthcare
See all newsPrestige Consumer Healthcare Inc. reports results for the quarter ended September 30 - Earnings Summary
Prestige Consumer Healthcare Q2 revenue beats on acquisition boost
Prestige Consumer Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
Brief: Prestige Consumer Healthcare Inc. Announces Offering Of $400 Million Senior Notes